Hi diddycat
1. The company has been undervalued for many years.
2. The company now has three potentially disruptive oncology platforms.
3. HER-Vaxx Phase 2 has reached it's finish line and as per latest update, its future trials have already been mapped out.
4. The company is now fully funded to choose its own path forward.
Ultimately what Imugene is worth, has a lot to do with what big pharma want and what they are willing to pay. Immuno-oncology in general holds a massive premium in the big pharma world. Imugene not only has potentially disruptive monotherapy candidates, but also combination therapy pairings for the top selling PD-1/PD-L1 drugs on the market.
"Pump and dump", not quite.
Perhaps speculation based off of science is more precise.
Why IMU is a multi multi bagger, page-3658
-
- There are more pages in this discussion • 21,771 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35252 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 1753430 | 24 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |